Traditional Chinese Medicine in Cancer Care: A Review of Controlled Clinical Studies Published in Chinese

Abstract

BackgroundTraditional Chinese medicine (TCM) has been widely applied for cancer care in China. There have been a large number of controlled clinical studies published in Chinese literature, yet no systematic searching and analysis has been done. This study summarizes the current evidence of controlled clinical studies of TCM for cancer.MethodsWe searched all the controlled clinical studies of TCM therapies for all kinds of cancers published in Chinese in four main Chinese electronic databases from their inception to November 2011. We bibliometrically analyzed the included studies and assessed the reporting quality.ResultsA total of 2964 reports (involving 253,434 cancer patients) including 2385 randomized controlled trials and 579 non-randomized controlled studies were included. The top seven cancer types treated were lung cancer, liver cancer, stomach cancer, breast cancer, esophagus cancer, colorectal cancer and nasopharyngeal cancer by both study numbers and case numbers. The majority of studies (72%) applied TCM therapy combined with conventional treatment, whilst fewer (28%) applied only TCM therapy in the experimental groups. Herbal medicine was the most frequently applied TCM therapy (2677 studies, 90.32%). The most frequently reported outcome was clinical symptom improvement (1667 studies, 56.24%) followed by biomarker indices (1270 studies, 42.85%), quality of life (1129 studies, 38.09%), chemo/radiotherapy induced side effects (1094 studies, 36.91%), tumor size (869 studies, 29.32%) and safety (547 studies, 18.45%). Completeness and adequacy of reporting appeared to improve with time.ConclusionsData from controlled clinical studies of TCM therapies in cancer treatment is substantial, and different therapies are applied either as monotherapy or in combination with conventional medicine. Reporting of controlled clinical studies should be improved based on the CONSORT and TREND Statements in future. Further studies should address the most frequently used TCM therapy for common cancers and outcome measures should address survival, relapse/metastasis and quality of life.

Cucurbitacin I inhibits cell migration and invasion and enhances chemosensitivity in colon cancer

“…Herbal medicine has attracted increased attention of medical scientists (27). Cucurbitacin I is a natural component extracted from plants of the Cucurbitaceae family, and exerts anticancer activities in glioblastoma, adenocarcinoma of the lung and breast cancer cells (11)(12)(13).…”

The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer

“…In the world including Western countries, TCM has been increasingly used in the last decades and has become well known for its significant role in preventing and treating cancer. It is estimated that the United States National Cancer Institute (NCI) spends around $120 million each year on TCM related research projects (6). According to conventional views, we believe that TCM possesses advantages as an adjuvant therapy to alleviate cancer symptoms at terminal stages when Western medicine treatments cannot offer any other treatment options.…”

Tanshinone IIA enhances chemosensitivity of colon cancer cells by suppressing nuclear factor-κB

“…Due to drug resistance and the toxic effect of current chemotherapy strategies, antitumor drug studies have been attempting to identify natural chemical compounds, and Chinese herbal medicine has been attracting increasing attention (36). TSA has been found to be an effective chemical component extracted from Danshen (Radix Salviae Miltiorrhizae) (37), which harbors anti-inflammatory and anti-oxidative activities (10)(11)(12)(13).…”